公开(公告)号：US11214627B2

公开(公告)日：2022-01-04

申请号：US16307454

申请日：2017-06-08

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph Adams ,  Thomas Allen Ceska ,  Anna Marie Davies ,  Alistair James Henry ,  Xiaofeng Liu ,  James Michael McDonnell ,  Brian John Sutton ,  Marta Katarzyna Westwood

IPC: C07K16/42 ,  C07K16/28 ,  C07K14/735 ,  A61P37/08

Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

公开(公告)号：US12054559B2

公开(公告)日：2024-08-06

申请号：US17541932

申请日：2021-12-03

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph Adams ,  Thomas Allen Ceska ,  Anna Marie Davies ,  Alistair James Henry ,  Xiaofeng Liu ,  James Michael McDonnell ,  Brian John Sutton ,  Marta Katarzyna Westwood

IPC: C07K16/42 ,  A61P37/08 ,  C07K14/735 ,  C07K16/28

CPC classification number: C07K16/4291 ,  A61P37/08 ,  C07K14/70535 ,  C07K16/2851 ,  C07K2317/565 ,  C07K2317/92

Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).